Drugs / NB1000S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04909723 | Jun 2021 → Nov 2022 | — | Novome Biotechnologies Inc | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NB1000S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04909723 ↗ |
| Modality | Other / unclassified | “a recombinant live biotherapeutic product” NCT04909723 ↗ |